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Abstract 
Background: Physiologic determinants, such as pulse pressure [difference between systolic blood pressure (SBP) and 
diastolic BP (DBP)], mean arterial pressure (2/3 DBP + 1/3 SBP), and double product [beats per minute (bpm) × SBP], 
are linked to cardiovascular outcomes. The effects of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibi-
tor, on pulse pressure, mean arterial pressure, and double product were assessed in patients with type 2 diabetes 
mellitus (T2DM).
Methods: This post hoc analysis was based on pooled data from four 26-week, randomized, double-blind, placebo-
controlled studies evaluating canagliflozin in patients with T2DM (N = 2313) and a 6-week, randomized, double-blind, 
placebo-controlled, ambulatory BP monitoring (ABPM) study evaluating canagliflozin in patients with T2DM and 
hypertension (N = 169). Changes from baseline in SBP, DBP, pulse pressure, mean arterial pressure, and double prod-
uct were assessed using seated BP measurements (pooled studies) or averaged 24-h BP assessments (ABPM study). 
Safety was assessed based on adverse event reports.
Results: In the pooled studies, canagliflozin 100 and 300 mg reduced SBP (−4.3 and −5.0 vs −0.3 mmHg) and 
DBP (−2.5 and −2.4 vs −0.6 mmHg) versus placebo at week 26. Reductions in pulse pressure (−1.8 and −2.6 
vs 0.2 mmHg), mean arterial pressure (−3.1 and −3.3 vs −0.5 mmHg), and double product (−381 and −416 vs 
−30 bpm × mmHg) were also seen with canagliflozin 100 and 300 mg versus placebo. In the ABPM study, canagliflo-
zin 100 and 300 mg reduced mean 24-h SBP (−4.5 and −6.2 vs −1.2 mmHg) and DBP (−2.2 and −3.2 vs −0.3 mmHg) 
versus placebo at week 6. Canagliflozin 300 mg provided reductions in pulse pressure (−3.3 vs −0.8 mmHg) and 
mean arterial pressure (−4.2 vs −0.6 mmHg) compared with placebo, while canagliflozin 100 mg had more modest 
effects on these parameters. Canagliflozin was generally well tolerated in both study populations.
Conclusions: Canagliflozin improved all three cardiovascular physiologic markers, consistent with the hypothesis 
that canagliflozin may have beneficial effects on some cardiovascular outcomes in patients with T2DM.
Trial registration ClinicalTrials.gov Identifier: NCT01081834 (registered March 2010); NCT01106677 (registered April 
2010); NCT01106625 (registered April 2010); NCT01106690 (registered April 2010); NCT01939496 (registered Septem-
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Background
Type 2 diabetes mellitus (T2DM) is associated with 
increased cardiovascular morbidity and mortality [1]. 
T2DM has been shown to be an independent risk factor 
for cardiovascular disease, and common comorbidities of 
T2DM, such as dyslipidemia and hypertension, can fur-
ther increase this risk [1, 2]. It is estimated that patients 
with T2DM and hypertension have a fourfold higher 
risk of developing cardiovascular disease compared 
with healthy individuals [2]. Furthermore, data from 
the Framingham Heart Study showed that patients with 
hypertension at the time of T2DM diagnosis had signifi-
cantly higher rates of all-cause mortality and cardiovas-
cular events compared with normotensive patients with 
T2DM [3]. The importance of effective blood pressure 
(BP) control to prevent cardiovascular events in patients 
with T2DM has been well established [1, 2]. Current 
guidelines recommend a target BP of <140/90 mmHg for 
most patients with T2DM and hypertension to reduce 
the risk of cardiovascular events, such as congestive heart 
failure and stroke [1, 4].
Arterial stiffness is also an established risk factor of 
cardiovascular events and mortality [5–7]. In particu-
lar, the physiologic determinants, such as pulse pressure 
{a surrogate for pulse wave velocity used to assess arte-
rial stiffness [difference between systolic BP (SBP) and 
diastolic BP (DBP)]}, mean arterial pressure [measure 
of cardiac output, systemic vascular resistance, and cen-
tral venous pressure (2/3 DBP +  1/3 SBP)], and double 
product [a measure of cardiac workload and myocardial 
oxygen demand (heart rate  ×  SBP)], have been linked 
to cardiovascular outcomes and may provide additional 
information for predicting cardiovascular disease risk [8, 
9]. Therefore, assessment of these surrogate BP param-
eters may be particularly relevant to assess cardiac effi-
ciency in patients with T2DM.
Canagliflozin is a sodium glucose co-transporter 2 
(SGLT2) inhibitor approved to treat adults with T2DM 
[10]. SGLT2 inhibition has been shown to increase uri-
nary glucose excretion (UGE), resulting in decreased 
plasma glucose levels in patients with T2DM [11–13]. 
Increased UGE also results in mild osmotic diuresis and 
a net caloric loss that contributes to reductions in body 
weight and BP [12, 14]. Across Phase 3 studies ranging 
from 26 to 104  weeks in duration, canagliflozin pro-
vided improvements in glycemic control and reductions 
in body weight and BP, with a favorable safety and toler-
ability profile, in a broad range of patients with T2DM as 
monotherapy or in combination with other antihypergly-
cemic agents (AHAs) [15].
In a pooled analysis of four placebo-controlled, Phase 
3 studies, canagliflozin treatment was associated with 
reductions in SBP at 26 weeks in both the overall popula-
tion of patients with T2DM and a subgroup of patients 
with elevated SBP at baseline (≥140  mmHg) [16]. A 
separate randomized, double-blind, placebo-controlled 
study assessing the immediate effects of canagliflozin on 
BP using ambulatory BP monitoring (ABPM) reported 
reductions in mean 24-h SBP after 6 weeks of canagliflo-
zin treatment in patients with T2DM and hypertension 
[17]. Using pooled data from the four 26-week, placebo-
controlled studies in a general population of patients with 
T2DM and data from the 6-week ABPM study in patients 
with T2DM and hypertension, this post hoc analysis 
assessed the immediate and longer-term changes in pulse 
pressure, mean arterial pressure, and double product 
with canagliflozin treatment.
Methods
Study design and patient populations
This post hoc analysis was based on data from two study 
populations: a pooled population consisting of four 
26-week, randomized, double-blind, placebo-controlled, 
Phase 3 studies evaluating canagliflozin in patients with 
T2DM (N  =  2313) and a 6-week, randomized, double-
blind, placebo-controlled study evaluating canagliflozin 
in patients with T2DM and hypertension (N = 169).
The four placebo-controlled studies included assess-
ments of canagliflozin 100 and 300  mg as monotherapy 
[18], add-on to metformin [19], add-on to metformin 
plus sulfonylurea [20], and add-on to metformin plus 
pioglitazone [21]. In the add-on to metformin study, 
patients were randomized to receive canagliflozin 100 
or 300 mg, sitagliptin 100 mg, or placebo once daily for 
26 weeks; data from the sitagliptin arm were not included 
in this analysis. All studies in the pooled population 
enrolled men and women aged 18–80 years with T2DM. 
The monotherapy study included patients with HbA1c 
≥7.0 and ≤10.0% and estimated glomerular filtration rate 
(eGFR) ≥50 mL/min/1.73 m2. The dual and triple therapy 
studies included patients with HbA1c ≥7.0 and ≤10.5% 
and eGFR ≥55 mL/min/1.73 m2. Patients were required 
to be on a stable antihypertensive medication regimen 
for ≥4  weeks prior to randomization; adjustments to 
antihypertensive medication considered clinically nec-
essary were to be made during the pretreatment phase 
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in order to avoid adjustments during the double-blind 
period. Key exclusion criteria common to all four stud-
ies included fasting plasma glucose (FPG) ≥15  mmol/L 
(≥270 mg/dL) during the pretreatment phase; history of 
type 1 diabetes mellitus (T1DM); history of myocardial 
infarction, unstable angina, revascularization procedure, 
or a cerebrovascular accident within 3 months of screen-
ing; and uncontrolled hypertension (i.e., the average of 
three seated BP readings with SBP ≥160 mmHg or DBP 
≥100 mmHg). Details of the study design, including ran-
domization and blinding, and glycemic rescue criteria 
have been previously reported for the individual studies 
included in the pooled analysis [18–21].
In the study evaluating canagliflozin in patients with 
T2DM and hypertension (N  =  169) using 24-h ABPM 
[17], patients were randomized to receive canagliflozin 
100 or 300  mg or placebo once daily for 6  weeks. The 
study included patients aged 18 to <75 years with T2DM 
and HbA1c ≥7.0 and <10.0% who were taking 1–3 AHAs, 
including metformin with or without sulfonylureas, thia-
zolidinediones, or dipeptidyl peptidase-4 inhibitors. 
Patients were also required to have hypertension (defined 
as a seated office SBP ≥130 and <160 mmHg and seated 
office DBP ≥70  mmHg) treated with stable doses of 
1–3 antihypertensive agents, including either an angio-
tensin-converting enzyme (ACE) inhibitor or angioten-
sin II receptor blocker (ARB), with or without calcium 
channel blockers, β-blockers, or diuretics other than 
loop diuretics. Key exclusion criteria included a diagno-
sis of T1DM or diabetic ketoacidosis; repeated (i.e., ≥2 
over a 1-week period) fasting self-monitored blood glu-
cose measurements ≥13.3  mmol/L (240  mg/dL) dur-
ing the pretreatment phase; uncontrolled hypertension 
(i.e., the average of three seated BP readings with SBP 
>160  mmHg or DBP >110  mmHg) at screening; treat-
ment with an SGLT2 inhibitor, insulin, or a glucagon-
like peptide-1 receptor agonist within 12  weeks prior 
to screening or in the 2-week run-in period; and treat-
ment with antihypertensive therapy (i.e., ACE inhibi-
tors, ARBs, loop diuretics, calcium channel blockers, or 
β-blockers) not on a stable regimen (i.e., same medica-
tions and doses) for ≥5 weeks prior to screening. Details 
of the study design, including randomization and blind-
ing, have been previously reported [17].
All studies included in this analysis were conducted in 
accordance with ethical principles that comply with the 
Declaration of Helsinki, and were consistent with Good 
Clinical Practices and applicable regulatory require-
ments. Study protocols and amendments were approved 
by institutional review boards and independent ethics 
committees at participating institutions. All patients pro-
vided written informed consent prior to participation in 
the studies.
Endpoints and assessments
Changes from baseline in SBP, DBP, pulse pressure, mean 
arterial pressure, and double product were assessed in 
the pooled, placebo-controlled studies at week 26 using 
seated BP measurements and in the ABPM study at 
week 6 using the averaged 24-h BP assessments. Pulse 
pressure was calculated as the difference between SBP 
and DBP. Mean arterial pressure was calculated as 
2/3 DBP  +  1/3 SBP. Double product was calculated as 
heart rate [beats per minute (bpm)] × SBP.
In the pooled, placebo-controlled studies, each seated 
BP measurement was based on an average of three BP 
readings taken manually with a mercury sphygmoma-
nometer or an automated BP monitor at intervals of 
≥1  min. In the ABPM study, BP recordings were col-
lected over a 24-h period using an ABPM device every 
20 min during the day and every 30 min during the night. 
Additional details regarding the methods used to meas-
ure BP have been previously reported for both study pop-
ulations [16, 17].
Safety and tolerability were assessed based on adverse 
event (AE) reports through week 26 in the pooled, 
placebo-controlled studies and through week 6 in the 
ABPM study. AEs were reported spontaneously by 
patients or in response to non-directed questioning and 
were coded using the Medical Dictionary for Regulatory 
Activities (MedDRA). The overall incidence of AEs and 
the incidence of volume depletion–related AEs were 
evaluated.
Statistical analyses
Analyses were performed using data from all randomized 
patients who received ≥1 dose of study drug. The last 
observation carried forward (LOCF) approach was used 
to impute missing data. Endpoints were analyzed using 
an analysis of covariance (ANCOVA) model, with treat-
ment and stratification factor (ABPM study) or study 
(pooled, placebo-controlled studies) as fixed effects and 
the corresponding baseline value as a covariate. Least 
squares (LS) mean differences and 2-sided 95% confi-
dence intervals (CIs) were estimated for the comparisons 
of each canagliflozin dose versus placebo. Safety analyses 
included all reported AEs (regardless of rescue therapy 
in the pooled, placebo-controlled studies), and included 
all randomized patients who received ≥1 dose of study 
drug. Statistical analyses were performed using SAS, ver-
sion 9.2 (Cary, NC, USA).
Results
Patients
Baseline demographic and disease characteristics were 
generally similar across treatment groups in both study 
populations (Table 1). In the pooled, placebo-controlled 
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studies, the mean baseline age was 56 years and patients 
had a mean baseline HbA1c of 8.0%, body mass index 
(BMI) of 32 kg/m2, and SBP of 128 mmHg. Of the 2313 
patients included in the pooled studies, 1332 (57.6%) 
were taking antihypertensive medication at baseline. 
In the ABPM study, the mean baseline age was 59 years 
and patients had a mean baseline HbA1c of 8.1%, BMI of 
33 kg/m2, and SBP of 139 mmHg. Mean baseline SBP and 
DBP were lower in the pooled, placebo-controlled stud-
ies, which included patients with and without hyperten-
sion, compared with the ABPM study, which enrolled 
only patients with hypertension.
Efficacy
Pooled, placebo‑controlled studies
In the pooled, placebo-controlled studies, canagliflozin 
100 and 300  mg provided reductions in SBP and DBP 
compared with placebo at week 26 (Fig.  1a). LS mean 
changes from baseline in SBP with canagliflozin 100 and 
300 mg and placebo were −4.3, −5.0, and −0.3 mmHg, 
respectively. LS mean changes from baseline in DBP with 
canagliflozin 100 and 300  mg and placebo were −2.5, 
−2.4, and −0.6 mmHg, respectively.
Both canagliflozin doses reduced pulse pressure, 
mean arterial pressure, and double product compared 
with placebo at week 26 (Figs. 2, 3, 4). LS mean changes 
from baseline in pulse pressure were −1.8, −2.6, and 
0.2  mmHg with canagliflozin 100 and 300  mg and pla-
cebo, respectively; LS mean changes in mean arterial 
pressure were −3.1, −3.3, and −0.5 mmHg, respectively. 
LS mean changes from baseline in double product were 
−381, −416, and −30 bpm × mmHg with canagliflozin 
100 and 300 mg and placebo, respectively.
ABPM study
In the ABPM study, canagliflozin 100 and 300  mg were 
associated with reductions in mean 24-h SBP and DBP 
compared with placebo at week 6 (Fig.  1b). LS mean 
reductions from baseline in mean 24-h SBP were −4.5, 
−6.2, and −1.2 mmHg with canagliflozin 100 and 300 mg 
and placebo, respectively. LS mean changes in mean 24-h 
DBP were −2.2, −3.2, and −0.3 mmHg, respectively.
Dose-dependent reductions from baseline in pulse 
pressure were seen with canagliflozin 100 and 300  mg 
compared with placebo at week 6 (LS mean changes of 
−2.3, −3.3, and −0.8 mmHg, respectively; Fig. 2). Dose-
dependent reductions were also seen in mean arterial 
pressure with both canagliflozin doses compared with 
placebo; LS mean changes from baseline were −3.0, 
−4.2, and −0.6 mmHg with canagliflozin 100 and 300 mg 
and placebo, respectively (Fig.  3). LS mean changes 
from baseline in double product were −410, −445, and 
Table 1 Baseline demographic and disease characteristics
ABPM ambulatory blood pressure monitoring, BMI body mass index, CANA canagliflozin, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate,  
PBO placebo, SD standard deviation, SBP systolic blood pressure, T2DM type 2 diabetes mellitus
a Data are mean (SD) unless otherwise indicated
b Percentages may not total 100% due to rounding
c Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported in the pooled, PBO-controlled 
studies; and includes other and unknown in the ABPM study














 Male 334 (52) 408 (49) 404 (48) 33 (59) 34 (60) 31 (55)
 Female 312 (48) 425 (51) 430 (52) 23 (41) 23 (40) 25 (45)
Age, years 56.3 (9.8) 55.9 (10.1) 55.7 (9.5) 59.6 (9.5) 57.8 (8.7) 58.3 (6.9)
Race, n (%)b
 White 470 (73) 591 (71) 610 (73) 46 (82) 45 (79) 43 (77)
 Black or African American 28 (4) 43 (5) 48 (6) 9 (16) 10 (18) 12 (21)
 Asian 82 (13) 103 (12) 100 (12) 0 1 (2) 1 (2)
 Otherc 66 (10) 96 (12) 76 (9) 1 (2) 1 (2) 0
HbA1c,  % 8.0 (0.9) 8.0 (0.9) 8.0 (1.0) 8.2 (0.9) 8.1 (0.9) 8.0 (0.8)
BMI, kg/m2 31.9 (6.4) 32.3 (6.4) 32.0 (6.5) 32.9 (5.7) 33.0 (6.0) 34.1 (6.8)
eGFR, mL/min/1.73 m2 87.0 (19.8) 88.3 (19.0) 88.8 (18.9) 87.9 (18.3) 87.2 (20.3) 85.6 (19.7)
Duration of T2DM, years 7.5 (6.2) 7.2 (5.8) 7.4 (6.2) 11.8 (8.7) 9.4 (6.0) 10.3 (6.2)
Seated SBP, mmHg 128.5 (13.2) 128.0 (12.8) 128.8 (12.8) 137.7 (8.6) 138.5 (11.1) 139.2 (8.8)
Seated DBP, mmHg 77.9 (8.3) 77.5 (8.0) 78.2 (8.3) 82.7 (8.6) 82.4 (7.7) 83.0 (8.2)
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−36  bpm ×  mmHg with canagliflozin 100 and 300  mg 
and placebo, respectively (Fig. 4).
Safety
Canagliflozin 100 and 300  mg were generally well tol-
erated in the pooled, placebo-controlled studies and in 
the ABPM study, with low incidences of serious AEs 
and AEs related to study discontinuation across treat-
ment groups in both studies [17, 22]. The tolerability 
profile of canagliflozin in both populations was gener-
ally consistent with previous studies, including a higher 
incidence of AEs related to the mechanism of SGLT2 
b
a
Fig. 1 Change from baseline in a SBP and b DBP [16, 17]. ABPM ambulatory blood pressure monitoring, CANA canagliflozin, CI confidence interval, 
DBP diastolic blood pressure, LS least squares, PBO placebo, SBP systolic blood pressure, SE standard error. a was adapted from [16], with permission 
from John Wiley and Sons
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inhibition (e.g., genital mycotic infections, osmotic diu-
resis–related AEs).
In the pooled, placebo-controlled studies, rates of vol-
ume depletion–related AEs (e.g., hypotension, postural 
dizziness, orthostatic hypotension) were low across 
groups (1.2, 1.3, and 1.1% with canagliflozin 100 and 
300  mg and placebo, respectively). Among patients 
treated with canagliflozin, no volume depletion–related 
Fig. 2 Change from baseline in pulse pressure. ABPM ambulatory blood pressure monitoring, CANA canagliflozin, CI confidence interval, LS least 
squares, PBO placebo, SE standard error
Fig. 3 Change from baseline in mean arterial pressure. ABPM ambulatory blood pressure monitoring, CANA canagliflozin, CI confidence interval,  
LS least squares, PBO placebo, SE standard error
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AEs were considered serious or led to study discontinua-
tion. In the ABPM study, 2 patients (3.6%) experienced a 
volume depletion–related AE with canagliflozin 300 mg; 
none were reported with canagliflozin 100 mg or placebo. 
Rates of significant orthostasis [defined as symptoms on 
standing (e.g., dizziness, lightheadedness) or a reduction 
in office SBP ≥20 mmHg or DBP ≥15 mmHg 2 min after 
standing] at week 6 were 3.8, 7.1, and 3.9%, with canagli-
flozin 100 and 300 mg and placebo, respectively.
Discussion
In the post hoc analysis of pooled data from four Phase 3 
studies, canagliflozin 100 and 300 mg provided reductions 
in SBP and DBP, as well as pulse pressure, mean arterial 
pressure, and double product compared with placebo over 
26  weeks in a broad population of patients with T2DM. 
Responses were generally similar in the post hoc analysis 
of data from a smaller, 6-week ABPM study in patients 
with T2DM and hypertension. Both canagliflozin doses 
reduced mean 24-h SBP and DBP over 6 weeks compared 
with placebo. Canagliflozin 300  mg provided reductions 
in pulse pressure and mean arterial pressure compared 
with placebo, while canagliflozin 100 mg had more mod-
est effects on these parameters. In both study populations, 
canagliflozin was generally well tolerated, with an increase 
in AEs related to the mechanism of SGLT2 inhibition 
(e.g., osmotic diuresis–related AEs), consistent with pre-
vious Phase 3 studies of canagliflozin [15].
The findings from this analysis are consistent with those 
reported for the SGLT2 inhibitor empagliflozin in a study 
that evaluated changes in BP and markers of arterial stiff-
ness and vascular resistance in patients with T2DM [23]. 
Empagliflozin provided significant reductions in SBP and 
DBP, pulse pressure, mean arterial pressure, and double 
product in a post hoc analysis of pooled 24-week data 
from four Phase 3 studies in patients with T2DM. Simi-
lar improvements were seen in a post hoc analysis of data 
from a 12-week ABPM study of empagliflozin in patients 
with T2DM and hypertension [23]. Collectively, the 
results from the canagliflozin and empagliflozin studies 
suggest that improvements in arterial stiffness and vas-
cular resistance may be class effects of SGLT2 inhibitors. 
Results from the current analysis demonstrated a reduc-
tion in BP and associated parameters within 6 weeks of 
initiating canagliflozin that persisted through 26  weeks 
of treatment. Earlier responses on BP with other SGLT2 
inhibitors have not been well characterized, but in the 
canagliflozin ABPM study, small numeric improvements 
in 24-h SBP were noted after 1 day of treatment. Of note, 
canagliflozin has been shown to provide a reduction in 
plasma volume within 1 week due to increased UGE and 
natriuresis, which may contribute to initial BP lowering 
in patients with T2DM [24].
The favorable effects of canagliflozin treatment on 
pulse pressure, mean arterial pressure, and double 
product are expected to translate into reduced arterial 
Fig. 4 Change from baseline in double product. ABPM ambulatory blood pressure monitoring, bpm beats per minute, CANA canagliflozin, CI confi-
dence interval, LS least squares, PBO placebo, SE standard error
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stiffness, improved blood flow, and a lower cardiac work-
load. Furthermore, as these markers have been shown to 
be predictive of cardiovascular events [8, 9, 25–27], the 
improvements in BP seen with canagliflozin treatment, 
in addition to reductions in HbA1c and body weight, may 
contribute to better cardiovascular outcomes in patients 
with T2DM. In the EMPA-REG OUTCOME trial, empa-
gliflozin showed a significant reduction in the risk for 
major adverse cardiovascular events, cardiovascular death, 
and hospitalization for heart failure compared with pla-
cebo in patients with T2DM and established cardiovascu-
lar disease [28]. It is not yet known whether the improved 
cardiovascular outcomes observed with empagliflozin 
apply to the entire SGLT2 inhibitor class, but recent meta-
analyses support favorable cardiovascular outcomes with 
SGLT2 inhibitors [29–34]. It has been hypothesized that 
the increase in osmotic diuresis associated with SGLT2 
inhibition results in a lower BP and intravascular volume 
that may help reduce cardiac workload [35, 36]; however, 
further studies are needed to define the cardioprotec-
tive mechanisms of SGLT2 inhibition. Results from the 
ongoing CANagliflozin cardioVascular Assessment Study 
(CANVAS; ClinicalTrials.gov Identifier: NCT01032629 
[37]) and CANVAS-R (renal endpoints; NCT01989754 
[38]) trials in patients with a history or high risk for car-
diovascular disease are expected in 2017 and will help 
determine whether the improvements in cardiovascular 
outcomes seen with empagliflozin are representative of the 
SGLT2 inhibitor class.
Limitations of the study include the post hoc nature of 
the analysis and the relatively small number of patients in 
the ABPM study population. In addition, double product 
may be best assessed using ABPM and many not accu-
rately predict cardiovascular risk in some patient popula-
tions [39]. However, the use of various measures in two 
different studies showing concordant results in two dif-
ferent study populations representing a broad range of 
patients with T2DM, including those with hypertension, 
strengthens the analysis.
Conclusions
Canagliflozin provided reductions in pulse pres-
sure, mean arterial pressure, and double product over 
26 weeks in a general population of patients with T2DM 
and in a 6-week ABPM study in patients with T2DM and 
hypertension. The improvements in cardiovascular phys-
iologic markers seen with canagliflozin in this analysis 
are consistent with the hypothesis that canagliflozin may 
have beneficial effects on some cardiovascular outcomes 
in patients with T2DM. Results from the ongoing CAN-
VAS and CANVAS-R trials may help to better define the 
cardioprotective effects of canagliflozin in patients with 
T2DM.
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